1h Free Analyst Time
Acute Respiratory Distress Syndrome - Pipeline Review, H2 2020Speak directly to the analyst to clarify any post sales queries you may have.
Summary
The publisher's latest Pharmaceutical and Healthcare disease pipeline guide Acute Respiratory Distress Syndrome - Pipeline Review, H2 2020, provides an overview of the Acute Respiratory Distress Syndrome (Respiratory) pipeline landscape.
Acute respiratory distress syndrome (ARDS) occurs when fluid fills up the air sacs in lungs. This leads to low oxygen levels in the blood. Common causes of ARDS include sepsis, inhalation of harmful substances, severe pneumonia and head or chest injury. Signs and symptoms of ARDS include severe shortness of breath, labored and unusually rapid breathing, low blood pressure and confusion and extreme tiredness.
Report Highlights
The publisher's Pharmaceutical and Healthcare latest pipeline guide Acute Respiratory Distress Syndrome - Pipeline Review, H2 2020, provides comprehensive information on the therapeutics under development for Acute Respiratory Distress Syndrome (Respiratory), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Acute Respiratory Distress Syndrome (Respiratory) pipeline guide also reviews of key players involved in therapeutic development for Acute Respiratory Distress Syndrome and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 11, 28, 22, 4, 50, 16 and 3 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 2 molecules, respectively.
Acute Respiratory Distress Syndrome (Respiratory) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Acute Respiratory Distress Syndrome (Respiratory).
- The pipeline guide reviews pipeline therapeutics for Acute Respiratory Distress Syndrome (Respiratory) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Acute Respiratory Distress Syndrome (Respiratory) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Acute Respiratory Distress Syndrome (Respiratory) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Acute Respiratory Distress Syndrome (Respiratory)
Reasons to Buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Acute Respiratory Distress Syndrome (Respiratory).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Acute Respiratory Distress Syndrome (Respiratory) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
IntroductionAcute Respiratory Distress Syndrome - Overview
Acute Respiratory Distress Syndrome - Therapeutics Development
Acute Respiratory Distress Syndrome - Therapeutics Assessment
Acute Respiratory Distress Syndrome - Companies Involved in Therapeutics Development
Acute Respiratory Distress Syndrome - Drug Profiles
Acute Respiratory Distress Syndrome - Dormant Projects
Acute Respiratory Distress Syndrome - Discontinued Products
Acute Respiratory Distress Syndrome - Product Development Milestones
Appendix
List of Tables
- Number of Products under Development for Acute Respiratory Distress Syndrome, H2 2020
- Number of Products under Development by Companies, H2 2020
- Number of Products under Development by Universities/Institutes, H2 2020
- Products under Development by Companies, H2 2020
- Products under Development by Universities/Institutes, H2 2020
- Number of Products by Stage and Target, H2 2020
- Number of Products by Stage and Mechanism of Action, H2 2020
- Number of Products by Stage and Route of Administration, H2 2020
- Number of Products by Stage and Molecule Type, H2 2020
- Acute Respiratory Distress Syndrome - Pipeline by A6 Pharmaceuticals LLC, H2 2020
- Acute Respiratory Distress Syndrome - Pipeline by AbbVie Inc, H2 2020
- Acute Respiratory Distress Syndrome - Pipeline by Abivax SA, H2 2020
- Acute Respiratory Distress Syndrome - Pipeline by Aerogen Ltd, H2 2020
- Acute Respiratory Distress Syndrome - Pipeline by Aerpio Pharmaceuticals Inc, H2 2020
- Acute Respiratory Distress Syndrome - Pipeline by Akebia Therapeutics Inc, H2 2020
- Acute Respiratory Distress Syndrome - Pipeline by Alexion Pharmaceuticals Inc, H2 2020
- Acute Respiratory Distress Syndrome - Pipeline by Algernon Pharmaceuticals Inc, H2 2020
- Acute Respiratory Distress Syndrome - Pipeline by Ampio Pharmaceuticals Inc, H2 2020
- Acute Respiratory Distress Syndrome - Pipeline by Amyndas Pharmaceuticals LLC, H2 2020
- Acute Respiratory Distress Syndrome - Pipeline by APEIRON Biologics AG, H2 2020
- Acute Respiratory Distress Syndrome - Pipeline by Apellis Pharmaceuticals Inc, H2 2020
- Acute Respiratory Distress Syndrome - Pipeline by Xfibra Inc, H2 2020
- Acute Respiratory Distress Syndrome - Dormant Projects, H2 2020
- Acute Respiratory Distress Syndrome - Discontinued Products, H2 2020
List of Figures
- Number of Products under Development for Acute Respiratory Distress Syndrome, H2 2020
- Number of Products under Development by Companies, H2 2020
- Number of Products by Top 10 Targets, H2 2020
- Number of Products by Stage and Top 10 Targets, H2 2020
- Number of Products by Top 10 Mechanism of Actions, H2 2020
- Number of Products by Stage and Top 10 Mechanism of Actions, H2 2020
- Number of Products by Top 10 Routes of Administration, H2 2020
- Number of Products by Stage and Top 10 Routes of Administration, H2 2020
- Number of Products by Top 10 Molecule Types, H2 2020
- Number of Products by Stage and Top 10 Molecule Types, H2 2020
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- A6 Pharmaceuticals LLC
- AbbVie Inc
- Abivax SA
- Aerogen Ltd
- Aerpio Pharmaceuticals Inc
- Akebia Therapeutics Inc
- Alexion Pharmaceuticals Inc
- Algernon Pharmaceuticals Inc
- Ampio Pharmaceuticals Inc
- Amyndas Pharmaceuticals LLC
- APEIRON Biologics AG
- Apellis Pharmaceuticals Inc
- Apeptico Forschung und Entwicklung GmbH
- Aptahem AB
- Aqualung Therapeutics Corp
- Arch Biopartners Inc
- Argenx SE
- Athersys Inc
- Ayuvis Research Inc
- Bayer AG
- Baylx Inc
- BeiGene Ltd
- BioCardia Inc
- Biocon Ltd
- BioMarck Pharmaceuticals Ltd
- Biophytis SA
- BioStem Technologies Inc
- Biotest AG
- Biovista Inc
- Bioxytran Inc
- Bonac Corp
- Bonus BioGroup Ltd
- BrainStorm Cell Therapeutics Inc
- CarthroniX Inc
- Ceapro Inc
- Cellenkos Inc
- Cellresearch Corp Pte Ltd
- Celularity Inc
- Cerecor Inc
- Chiesi Farmaceutici SpA
- China Grand Pharmaceutical and Healthcare Holdings Ltd
- CohBar Inc
- Commence Bio Inc
- Curacle Co Ltd
- Cynata Therapeutics Ltd
- Cytopeutics Pte Ltd
- Diffusion Pharmaceuticals Inc
- Dimerix Ltd
- Edesa Biotech Inc
- Educell doo
- Emergent BioSolutions Inc
- Emtora Biosciences
- Enzychem Lifesciences Corp
- Eunoia Biotech LLC
- EUSA Pharma (UK) Ltd
- Evgen Pharma Plc
- Exvastat Ltd
- F4 Pharma GmbH
- Faron Pharmaceuticals Oy
- FibroGenesis LLC
- Foresee Pharmaceuticals Co Ltd
- Grifols SA
- Hemarina SA
- Histocell SL
- Human Life CORD Japan Inc
- Hydra Biosciences Inc
- Iltoo Pharma
- Immune Regulation Ltd
- IMMvention Therapeutix Inc
- Implicit Bioscience Ltd
- Impression Healthcare Ltd
- Imstem Biotechnology Inc
- In2cure AB
- Insmed Inc
- IsletOne AB
- Khondrion BV
- Koligo Therapeutics Inc
- Kubota Vision Inc
- Kyorin Pharmaceutical Co Ltd
- Lamellar Biomedical Ltd
- Lattice Biologics Ltd
- Leading BioSciences Inc
- Liminal BioSciences Inc
- LTT Bio-Pharma Co Ltd
- MannKind Corp
- Matrix Biomed Inc
- Meridigen Biotech Co Ltd
- Mesoblast Ltd
- Nano Biotherapeutics Inc
- NantKwest Inc
- Neutrolis Inc
- Northern Therapeutics Inc
- Novellus Inc
- Noxopharm Ltd
- NS Pharma Inc
- Orbsen Therapeutics Ltd
- Oryzon Genomics SA
- PharmAbcine Inc
- Pharming Group NV
- PhaseBio Pharmaceuticals Inc
- Pluristem Therapeutics Inc
- Predictive Biotech Inc
- R Pharm
- Relief Therapeutics Holding AG
- Restore Therapeutics LLC
- Reven Pharmaceuticals Inc
- Roivant Sciences Ltd
- Santhera Pharmaceuticals Holding AG
- Savara Inc
- SFA Therapeutics LLC
- SolAeroMed Inc
- SynAct Pharma AB
- Syndax Pharmaceuticals Inc
- Thetis Pharmaceuticals LLC
- Trevena Inc
- Vasomune Inc
- Veru Inc
- Windtree Therapeutics Inc
- Xfibra Inc
